AzTrials
AzTrials

Cardiac Devices InfectionPhase 4RAIDNCT06203769

Reduction of Antibiotherapy Duration for Infections on Implantable Extra Cardiac Devices Leads

A Phase 4 study testing 14-day antibiotic therapy and 28-day antibiotic therapy in people with Cardiac Devices Infection, run by Assistance Publique - Hôpitaux de Paris.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The design is an Open-label randomized controlled multicenter non-inferiority trial with blinded assessor which compares 2 antibiotic strategy: 14-day antibiotic therapy after removal of infected material (experimental group) versus 28-day antibiotic therapy after removal of infected material (control group). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cardiac Devices Infection
What is being tested?
14-day antibiotic therapy and 28-day antibiotic therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
500 participants
Where
No sites listed yet
Study dates
30 Jun 2024to 30 Jun 2028
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years
  • Diagnosis of CIED leads infections, defined by:
  • Symptoms/signs of systemic infection AND positive blood cultures fulfilled the major Duke microbiological criteria AND echocardiography consistent with vegetation(s) attached to lead(s) AND/OR [18F]FDG PET/CT or radiolabelled WBC SPECT/CT detection of abnormal activity along leads OR
  • Symptoms/signs of systemic infection AND NO, signs of generator pocket infection, AND culture, histology or molecular evidence of infection on explanted lead.
  • Complete removal of the infected CIED
  • Signed informed consent
  • French National Health Assurance

Who cannot join

  • Current involvement of native or prosthetic heart valve
  • Distant infectious foci (such as haematogenous vertebral osteomyelitis, pulmonary abscess…) justifying a prolonged duration of therapy.
  • Positive blood culture > 24 hours after cultures despite CIED removal
  • CIED infection with Mycobacteria or Fungi
  • Women who are pregnant or nursing
  • Females of childbearing potential without effective method of birth control
  • Patients who are under tutorship or curatorship

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Raphael LEPEULE, Infectiologue contact

01.45.17.80.03 ext. 33

raphael.lepeule@aphp.fr

Candy ESTEVEZ, Project Manager contact

01.44.84.17.47 ext. 33

candy.estevez@aphp.fr

About this study

Official title: Reduction of Antibiotherapy Duration for Infections on Implantable Extra Cardiac Devices Leads: a Randomized Controlled Multicenter Non-inferiority Trial

The design is an Open-label randomized controlled multicenter non-inferiority trial with blinded assessor which compares 2 antibiotic strategy: 14-day antibiotic therapy after removal of infected material (experimental group) versus 28-day antibiotic therapy after removal of infected material (control group).

Randomization will be centralized, individual 1:1, stratified on center and age (<75 versus >=75 years). Analysis will be reported following CONSORT guidelines for pharmacological trials.

Main analysis will be conducted according to per protocol and intent-to-treat principles. Subgroup analysis will be conducted according to age, classes of antibiotics at baseline and according to resistance testing and baseline renal clearance.

Read the detailed description

Infections of cardiac implantable electronic devices (CIED) are one of the most frequent complication after implantation of these devices, with an incidence rate estimated at 4.82 / 1000 in Denmark, mainly in the first year post implantation. An american study found that the incidence of CIED infection in the USA increased from 1.53% in 2004 to 2.41% in 2008 and a National Inpatient Sample database study showed an increase from 1.45% to 3.41% (P<0.001) from 2000 through 2012. These figures are constantly increasing and concern mostly older people.

Although the mortality seems to be low compared to those of valvular infection , evaluated at 4% for nonstaphylococcal infection and up to 9% for Staphylococcus aureus related infections, those infections are responsible of numerous morbidities such as iterative hospitalizations, decompensations of other comorbidities and autonomy loss, especially, for older people

Clinical presentations of CIED infections are varied and include generator pocket infections, native or prosthetic CIED-associated valvular endocarditis (CIED-IE) with echocardiographic evidence of valve involvement, and CIED lead infections (CIED-LI) with evidence of lead infection without valve involvement.

In CIED infections, removal of the device is the cornerstone of treatment and is usually required to enable cure in association with antimicrobial therapy for a few weeks. However, although antimicrobial therapy duration after removal of the device are relatively well defined for generator pocket infections (10 - 14 days for the remaining skin and soft tissue infection) and CIED-IE (4 - 6 weeks), the optimal duration of antibiotic treatment in CIED-LI has yet to be determined.

Several series amalgamate generator pocket infection, CIED-IE and CIED-LI descript duration of therapy and are therefore unhelpful in deciding on the optimum duration of antimicrobials.

Guidelines for management of CIED infections recommend different durations of antibiotic treatment, particularly for CIED-LI, which can result in considerable inappropriate antimicrobial exposure in a vulnerable patient population.

In light of the emergence of bacterial resistance and in order to limit the drug toxicities of antibiotics, it is crucial to offer patients the shortest possible duration of treatment, without losing efficiency.

Infections of cardiac implantable electronic devices (CIED) are one of the most frequent complication after implantation of these devices, with an incidence rate estimated at 4.82 / 1000 in Denmark, mainly in the first year post implantation(1). An american study found that the incidence of CIED infection in the USA increased from 1.53% in 2004 to 2.41% in 2008 and a National Inpatient Sample database study showed an increase from 1.45% to 3.41% (P<0.001) from 2000 through 2012. These figures are constantly increasing and concern mostly older people.

Although the mortality seems to be low compared to those of valvular infection , evaluated at 4% for nonstaphylococcal infection and up to 9% for Staphylococcus aureus related infections (4), those infections are responsible of numerous morbidities such as iterative hospitalizations, decompensations of other comorbidities and autonomy loss, especially, for older people

Clinical presentations of CIED infections are varied and include generator pocket infections, native or prosthetic CIED-associated valvular endocarditis (CIED-IE) with echocardiographic evidence of valve involvement, and CIED lead infections (CIED-LI) with evidence of lead infection without valve involvement.

In CIED infections, removal of the device is the cornerstone of treatment and is usually required to enable cure in association with antimicrobial therapy for a few weeks. However, although antimicrobial therapy duration after removal of the device are relatively well defined for generator pocket infections (10 - 14 days for the remaining skin and soft tissue infection) and CIED-IE (4 - 6 weeks) (5), the optimal duration of antibiotic treatment in CIED-LI has yet to be determined.

Several series amalgamate generator pocket infection, CIED-IE and CIED-LI descript duration of therapy and are therefore unhelpful in deciding on the optimum duration of antimicrobials .

Guidelines for management of CIED infections recommend different durations of antibiotic treatment, particularly for CIED-LI, which can result in considerable inappropriate antimicrobial exposure in a vulnerable patient population.

In light of the emergence of bacterial resistance and in order to limit the drug toxicities of antibiotics, it is crucial to offer patients the shortest possible duration of treatment, without losing efficiency.

To this regard, renal failure is one of the most frequent adverse effect during antibiotic treatment, especially in older patients with polymedication and comorbidities, and is responsible indirectly of increasing mortality.

Furthermore, shortening antibiotic therapy would allow to decrease the number of allergy events and Clostridium difficile colitis.

In the most recent European recommendations , if the TEE performed after device removal shows no signs of valve vegetation (i.e. isolated lead vegetation), the follow-up blood cultures are negative, the clinical improvement is good and there are no pulmonary abscesses, treatment duration for 2 weeks post-device extraction can be sufficient but total treatment duration should not be shorter than 4 weeks.

Older U.S guidelines recommend at least 2 weeks of parenteral therapy after extraction of an infected device for patients with bloodstream infection. Patients with sustained (>24 hours) positive blood cultures despite CIED removal and appropriate antimicrobial therapy should receive parenteral therapy for at least 4 weeks, even if TEE is negative for valvular vegetations.

In the British recommendations short course therapy (2 weeks) could be considered if tricuspid valve is structurally normal, no ghost lesions present after system removal on control TEE and rapid clinical response to device removal.

Finally, no clinical trial data are available to define the optimal duration of antimicrobial therapy for CIED-LI and all recommendations are based on retrospective studies and expert opinion. U.S guidelines are mainly based on one retrospective, non-randomized, monocenter cohort study leading to possible confusion and indication bias. However, this study, which is to our knowledge the only one on this topic, 189 patients were included from 1991 to 2003 and presented either a generator pocket infections, a CIED-IE, or a CIED-LI without valvular infection. All results were "pooled" together when describing duration of therapy and are therefore unhelpful in deciding on the optimum duration of antimicrobials. Besides, english recommendations are based on expert opinions, themselves based on case series and pharmacological considerations .

Our hypothesis is therefore that in CIED-LI, 14 days of antimicrobial therapy after device extraction is sufficient regardless of the duration of previous antibiotic therapy if the bacteremia is controlled and if there are (i) no distant infectious foci (abscess), no valvular lesions

Therefore the benefit-risk balance of a shortening of antibiotic therapy for CIED infections needs to be assessed with a high-level of evidence.

This study is endorsed by AEPEI

Being tested
14-day antibiotic therapy, 28-day antibiotic therapy
Keywords
Infections, Antibiotherapy, Implantable extra cardiac devices, Non-inferiority, Randomized
Medical subject headings
Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 14-day antibiotic therapyDrug

    Also called Experimental arm

    The studied intervention will be 14-day antibiotic therapy after removal of infected material

  • 28-day antibiotic therapyDrug

    Also called Control arm

    The comparator arm will be 28-day antibiotic therapy after removal of infected material

Study groups in NCT06203769
Study groupRoleWhat they receive
Experimental groupExperimental14-day antibiotic therapy after removal of infected material
Receives: Drug: 14-day antibiotic therapy
control groupActive comparator28-day antibiotic therapy after removal of infected material
Receives: Drug: 28-day antibiotic therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mortality,

    Mortality linked to infection during or after antibiotic therapy

    Measured: at 3 months after randomization,

  2. Rate of relapse of infection

    Rate of relapse of infection defined by diagnostic of endocarditis or CIED infection with the same bacteria

    Measured: at 3 months after randomization

  3. Rate of relapse of infection

    Number of patient whith relapse of infection defined by diagnostic of endocarditis or CIED infection with the same bacteria

    Measured: at 6 months after randomization

  4. Rate of a distant infections

    Rate of a distant infectious foci with the same bacteria

    Measured: at 3 months after randomization

  5. Rate of a distant infectious

    Rate of diagnostic of a distant infectious foci with the same bacteria

    Measured: 6 months after randomization

Secondary outcomes (10)
  1. Rate of Acute Renal failure,

    rate of Acute Renal failure at the end of the antibiotherapy

    Measured: at the end of the antibiotherapy period

  2. Rate of Acute Renal failure,

    Rate of Acute Renal failure at 3 months after the end of the antibiotherapy antibiotherapy

    Measured: at 3 months after the end of the antibiotherapy

  3. Rate of Acute Renal failure,

    The Rate of Acute Renal failure at 6 months after the end of the antibiotherapy

    Measured: at 6 months after the end of the antibiotherapy

  4. Rate of Clostridium difficile colitis,

    The measurements of the event occuring will be taken at 3 months after the end of the antibiotherapy périod

    Measured: at 3 months after the end of antibiotherapy

  5. Rate of Clostridium difficile colitis,

    The measurements of the event occuring will be taken at 6 months afte rthe end of the antibiotherapy périod

    Measured: at 6 months after the end of antibiotherapy

  6. Rate of allergy grade III or IV

    The measurements of the event occuring will be taken at 3 months after the end of the antibiotherapy périod

    Measured: at 3 months after the end of antibiotherapy

  7. Rate of allergy grade III or IV

    The measurements of the event occuring will be taken at 6 months after the end of the antibiotherapy périod

    Measured: at 6 months after the end of antibiotherapy

  8. Percentage of unplanned hospitalization

    Percentage of unplanned hospitalization within 6 months after the end of antibiotherapy

    Measured: within 6 months after the end of antibiotherapy

  9. Percentage of emergency consultation,

    Percentage of emergency consultation within 6 months after the end of antibiotherapy

    Measured: within 6 months after the end of antibiotherapy

  10. percentage of adverse events related to antibiotherapy

    Percentage of adverse events related to antibiotherapy within 6 months after the end of antibiotherapy

    Measured: within 6 months after the end of antibiotherapy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jan 2024
  2. Study start30 Jun 2024 (estimated)
  3. Primary completion30 Jan 2028 (estimated)
  4. Study completion30 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06203769
Sponsor's protocol ID
APHP220013
Acronym
RAID
Status last verified
Jan 2024
First submitted
29 Nov 2023
Last updated
12 Jan 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing 14-day antibiotic therapy and 28-day antibiotic therapy in people with Cardiac Devices Infection, run by Assistance Publique - Hôpitaux de Paris.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 12 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Raphael LEPEULE, Infectiologue (01.45.17.80.03 ext. 33, raphael.lepeule@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mortality, (time frame: at 3 months after randomization,). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in